Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
45
XPH Quote, Financials, Valuation and Earnings
Last price:
$42.55
Seasonality move
:
-0.24%
Day range:
$42.20 - $42.75
52-week range:
$35.22 - $48.76
Dividend yield:
1.41%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
11.6K
Avg. volume:
51.5K
1-year change:
1.4%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XPH
SPDR S&P Pharmaceuticals ETF
|
$42.62 | -- | -- | -- | $0.10 | 1.41% | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
$165.47 | -- | -- | -- | $1.17 | 0.71% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$65.62 | -- | -- | -- | $0.13 | 0.25% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$83.12 | -- | -- | -- | $0.27 | 1.16% | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
$77.89 | -- | -- | -- | $0.02 | 0.07% | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
$92.98 | -- | -- | -- | $0.06 | 0.3% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | 0.358 | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | 0.653 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 0.915 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | 0.248 | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | 1.330 | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | 1.060 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- | -- |
SPDR S&P Pharmaceuticals ETF vs. Competitors
-
Which has Higher Returns XPH or FBT?
First Trust NYSE Arca Biotechnology Index Fund has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat First Trust NYSE Arca Biotechnology Index Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XPHSPDR S&P Pharmaceuticals ETF-- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- -
What do Analysts Say About XPH or FBT?
SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust NYSE Arca Biotechnology Index Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than First Trust NYSE Arca Biotechnology Index Fund, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than First Trust NYSE Arca Biotechnology Index Fund.
Company Buy Ratings Hold Ratings Sell Ratings XPHSPDR S&P Pharmaceuticals ETF0 0 0 FBTFirst Trust NYSE Arca Biotechnology Index Fund0 0 0 -
Is XPH or FBT More Risky?
SPDR S&P Pharmaceuticals ETF has a beta of 0.623, which suggesting that the stock is 37.686% less volatile than S&P 500. In comparison First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.641, suggesting its less volatile than the S&P 500 by 35.874%.
-
Which is a Better Dividend Stock XPH or FBT?
SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.10 per share corresponding to a yield of 1.41%. First Trust NYSE Arca Biotechnology Index Fund offers a yield of 0.71% to investors and pays a quarterly dividend of $1.17 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. First Trust NYSE Arca Biotechnology Index Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XPH or FBT?
SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than First Trust NYSE Arca Biotechnology Index Fund quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than First Trust NYSE Arca Biotechnology Index Fund's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while First Trust NYSE Arca Biotechnology Index Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for First Trust NYSE Arca Biotechnology Index Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XPHSPDR S&P Pharmaceuticals ETF-- -- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- --
-
Which has Higher Returns XPH or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XPHSPDR S&P Pharmaceuticals ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About XPH or PBE?
SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings XPHSPDR S&P Pharmaceuticals ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is XPH or PBE More Risky?
SPDR S&P Pharmaceuticals ETF has a beta of 0.623, which suggesting that the stock is 37.686% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.810, suggesting its less volatile than the S&P 500 by 19.007%.
-
Which is a Better Dividend Stock XPH or PBE?
SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.10 per share corresponding to a yield of 1.41%. Invesco Biotechnology & Genome ETF offers a yield of 0.25% to investors and pays a quarterly dividend of $0.13 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XPH or PBE?
SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XPHSPDR S&P Pharmaceuticals ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns XPH or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XPHSPDR S&P Pharmaceuticals ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About XPH or PJP?
SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings XPHSPDR S&P Pharmaceuticals ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is XPH or PJP More Risky?
SPDR S&P Pharmaceuticals ETF has a beta of 0.623, which suggesting that the stock is 37.686% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.502, suggesting its less volatile than the S&P 500 by 49.771%.
-
Which is a Better Dividend Stock XPH or PJP?
SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.10 per share corresponding to a yield of 1.41%. Invesco Pharmaceuticals ETF offers a yield of 1.16% to investors and pays a quarterly dividend of $0.27 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XPH or PJP?
SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XPHSPDR S&P Pharmaceuticals ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns XPH or XHE?
SPDR S&P Health Care Equipment ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat SPDR S&P Health Care Equipment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XPHSPDR S&P Pharmaceuticals ETF-- -- -- XHESPDR S&P Health Care Equipment ETF-- -- -- -
What do Analysts Say About XPH or XHE?
SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Equipment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than SPDR S&P Health Care Equipment ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than SPDR S&P Health Care Equipment ETF.
Company Buy Ratings Hold Ratings Sell Ratings XPHSPDR S&P Pharmaceuticals ETF0 0 0 XHESPDR S&P Health Care Equipment ETF0 0 0 -
Is XPH or XHE More Risky?
SPDR S&P Pharmaceuticals ETF has a beta of 0.623, which suggesting that the stock is 37.686% less volatile than S&P 500. In comparison SPDR S&P Health Care Equipment ETF has a beta of 1.047, suggesting its more volatile than the S&P 500 by 4.673%.
-
Which is a Better Dividend Stock XPH or XHE?
SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.10 per share corresponding to a yield of 1.41%. SPDR S&P Health Care Equipment ETF offers a yield of 0.07% to investors and pays a quarterly dividend of $0.02 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Equipment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XPH or XHE?
SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Equipment ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than SPDR S&P Health Care Equipment ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Equipment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for SPDR S&P Health Care Equipment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XPHSPDR S&P Pharmaceuticals ETF-- -- -- -- XHESPDR S&P Health Care Equipment ETF-- -- -- --
-
Which has Higher Returns XPH or XHS?
SPDR S&P Health Care Services ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat SPDR S&P Health Care Services ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XPHSPDR S&P Pharmaceuticals ETF-- -- -- XHSSPDR S&P Health Care Services ETF-- -- -- -
What do Analysts Say About XPH or XHS?
SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than SPDR S&P Health Care Services ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than SPDR S&P Health Care Services ETF.
Company Buy Ratings Hold Ratings Sell Ratings XPHSPDR S&P Pharmaceuticals ETF0 0 0 XHSSPDR S&P Health Care Services ETF0 0 0 -
Is XPH or XHS More Risky?
SPDR S&P Pharmaceuticals ETF has a beta of 0.623, which suggesting that the stock is 37.686% less volatile than S&P 500. In comparison SPDR S&P Health Care Services ETF has a beta of 1.018, suggesting its more volatile than the S&P 500 by 1.773%.
-
Which is a Better Dividend Stock XPH or XHS?
SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.10 per share corresponding to a yield of 1.41%. SPDR S&P Health Care Services ETF offers a yield of 0.3% to investors and pays a quarterly dividend of $0.06 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XPH or XHS?
SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Services ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than SPDR S&P Health Care Services ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XPHSPDR S&P Pharmaceuticals ETF-- -- -- -- XHSSPDR S&P Health Care Services ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
71
PGY alert for Jul 18
Pagaya Technologies [PGY] is up 4.2% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is down 0.01% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 9.06% over the past day.
